ORAL 5 FU PLUS 776C85 WITH/ WITHOUT LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

ORAL 5 FU PLUS 776C85 含/不含亚叶酸治疗转移性结直肠癌

• 批准号: 6246867
• 负责人: HOWARD S HOCHSTER
• 金额: $ 2.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-12 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246867
• 关键词: 5 fluorouridine; antineoplastics; clinical research; colorectal neoplasms; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; leucovorin; metastasis; neoplasm /cancer chemotherapy; quality of life

The main objectives of this Phase II study are to evaluate the safety and efficacy of 5 day oral 5-FU given in combination with 776C85 with or without Leukocorin in the treatment of previously untreated or refractory metastatic colorectal cancer. The protocol will obtain preliminary data on whether the type of 5-FU resistance affects the antitumor activity of 5-FU plus 776C85. Quality of life (QOL) and validation of a site specific QOL module used as a supplement to a core questionairre will also be evaluated.

该第二阶段研究的主要目标是评估安全性和 5 天口服 5-FU 与 776C85 联合用药的疗效 不含白细胞素用于治疗先前未经治疗或难治的患者 转移性结直肠癌。 协议将获得初步数据 5-FU耐药类型是否影响其抗肿瘤活性 5-FU 加 776C85。生活质量 (QOL) 和特定地点的验证 用作核心问卷补充的 QOL 模块也将 评价。